dasatinib teva 70 mg
teva b.v., holandsko - dazatinib - 44 - cytostatica
dasatinib teva 50 mg
teva b.v., holandsko - dazatinib - 44 - cytostatica
dasatinib msn 140 mg
msn labs europe limited, malta - dazatinib - 44 - cytostatica
dasatinib msn 100 mg
msn labs europe limited, malta - dazatinib - 44 - cytostatica
dasatinib msn 80 mg
msn labs europe limited, malta - dazatinib - 44 - cytostatica
dasatinib msn 70 mg
msn labs europe limited, malta - dazatinib - 44 - cytostatica
dasatinib msn 50 mg
msn labs europe limited, malta - dazatinib - 44 - cytostatica
dasatinib msn 20 mg
msn labs europe limited, malta - dazatinib - 44 - cytostatica
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pozri časti 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
bosulif
pfizer europe ma eeig - bosutinib (ako monohydrát) - leukémia, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif je indikovaný na liečbu dospelých pacientov s:novo‑diagnostikovaná chronická fáza (cp) chromozóm philadelphia-pozitívne chronické myelogenous leukémia (ph+ cml). cp, zrýchlené fáza (ap), a odstreľovanie fáza (bp) ph+ cml predtým liečení jeden alebo viac tyrozín kinase inhibítor(s) [tki(y)] a pre koho imatinib, nilotinib a dasatinib nie sú považované za primerané možnosti liečby.